MedTrace Logo

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-03-23

Study results available
· View outcomes & findings →

Summary

This study proposes to compare the efficacy of sumatriptan and aspirin to placebo as an acute abortive treatment for delayed alcohol induced headache in adult subjects.

Conditions

  • Delayed Alcohol Induced Headache

Interventions

DRUG

VVD-101

All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.

DRUG

Placebo

All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.

Sponsors & Collaborators

  • Vivid Pharma Inc.

    collaborator INDUSTRY

  • Cady, Roger, M.D.

    lead INDIV

Principal Investigators

  • Roger K Cady, MD · Clinvest

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176655 on ClinicalTrials.gov